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Abstract 
Background: To date the TGF-β1 activation mediated by integrin ανβ5 during fibrosis is well-known. This process has 
been shown also in the heart, where cardiac fibroblasts (CF) differentiate into α-smooth muscle actin (α-SMA)-positive 
myofibroblasts (MyoFB). Here, we studied the effects on CF, isolated by spontaneously hypertensive rats (SHR), of 
integrin ανβ5 inhibition in MyoFB differentiation.
Methods: Staining and immunohistochemistry were performed on rat cardiac tissue. CF were isolated by enzymatic 
digestion from SHR (SHR-CF) and normotensive WKY (WKY-CF) rat hearts and then treated for in vitro evaluation.
Results: SHR heart tissues revealed a higher TGF-β1 expression vs. WKY samples. SHR-CF showed an enhanced 
SMAD2/3 activation and an up-regulated expression of α-SMA, a typical MyoFB marker, especially after TGF-β1 treat-
ment. Immunostaining on cardiac tissues revealed a higher expression of integrin ανβ5 in SHR vs. WKY rat hearts. 
In vitro results confirmed the up-regulation of integrin ανβ5 expression in SHR-CF at basal condition and after TGF-β1 
treatment, in comparison with WKY-CF. Inhibition of integrin ανβ5 by cilengitide treatment led a decreased expres-
sion of ανβ5, collagen I, and α-SMA in SHR-CF vs. WKY-CF, resulting in a diminished differentiation of CF into MyoFB. 
Taking together, results suggested that SHR-CF are more susceptible to TGF-β1, showing an up-regulated activation 
of SMAD2/3 signaling, and an increased ανβ5, α-SMA, and collagen I expression. Hypertension stimulus promoted an 
up-regulation of integrin ανβ5 on SHR cardiac tissue and its in vitro inhibition reverted pro-fibrotic events of SHR-CF.
Conclusion: Inhibition of integrin ανβ5 exerted by cilengitide strongly diminished SHR-CF differentiation into detri-
mental MyoFB. So, integrin ανβ5 might be considered a novel therapeutic target and cilengitide an effective pharma-
cological tool to limit the progression of hypertension-induced cardiac fibrosis.
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Background
Arterial hypertension is one of the main cause of cardiac 
remodelling, which commonly culminates in left ventric-
ular hypertrophy (LVH) in about 15–20% of hypertensive 
patients [1]. Although current anti-hypertensive drugs 
reduce arterial blood pressure, these treatments are 
partially effective in reducing or reverting the hyperten-
sive-derived cardiac fibrosis. Thus, the identification of 
further targets is extremely relevant in this pathological 
context, in order to define novel and proper therapeutic 
strategies.
In the last 20  years, the transforming growth 
factor-β1 (TGF-β1) has emerged as a crucial mediator 
of the local cardiac remodelling, not only in hyperten-
sive pathological scenario [2], but also in other cardiac 
disease [3]. In particular, active TGF-β1 enhances the 
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differentiation of fibroblasts into contractile myofi-
broblasts (MyoFB), by promoting the expression of 
α-smooth muscle actin (α-SMA) [4, 5], and the secre-
tion of detrimental pro-fibrotic collagen in extracellular 
matrix (ECM) [6]. Thus, persistent activation of MyoFB 
results in the formation of scars, which determines an 
increased ECM stiffness and leading to an impaired 
heart function [7].
Although the TGF-β1 activation models are numer-
ous, among these the integrin-mediated mechanotrans-
duction of TGF-β1 release from its latent complex in 
ECM is gaining in last years a strong relief [8, 9]. This 
model has been primarily described starting from stud-
ies on lung and skin fibrotic disease [10–12]. In fact, 
it has been reported in these pathologies that several 
integrins are able to bind the ECM component of TGF-
β1 latent complex and to release TGF-β1 by mechanical 
stretching [13–16].
Among these integrins, the integrin ανβ5, consti-
tutively expressed in normal cardiac tissue, has been 
shown to mediate the adhesion of rat fibroblasts to vit-
ronectin in ECM [17]. In addition, Sarrazy et  al. have 
recently shown that human cardiac fibroblasts (CF) are 
able to differentiate into contractile MyoFB by integrin-
mediated TGF-β1 activation in a pig model of LVH 
[18].
Although in other pathological contexts (i.e. glioblas-
toma, pancreatic and breast cancer, idiopathic pulmo-
nary fibrosis) the integrin-mediated TGF-β1 activation 
is a well-known pharmacological axis and several com-
pounds have been already included in clinical trials [19], 
the involvement of this molecular mechanism, as well 
as its inhibition, in hypertension-derived cardiac fibro-
sis has not been yet evaluated. In depth, cilengitide is an 
effective ανβ5 integrin inhibitor, which has been studied 
in the last 10 years as therapeutic compound in a series of 
pre-clinical and clinical trials [20–24].
Thus, aims of this study are the investigation in hyper-
tension context of TGF-β1 signaling activation in terms 
of integrin ανβ5 expression, both in heart tissue and in 
CF isolated from hypertensive rats, and the in vitro mod-
ulation of this axis exerted by specific integrin inhibitor.
Methods
Animals
8-week-old male normotensive Wistar Kyoto rats (WKY, 
n = 10) and Spontaneously Hypertensive rats (SHR, 
n = 10) were housed in collective cages under 14–10  h 
light/dark cycles in a temperature-controlled room 
(22  °C). In order to confirm hypertension in the SHR 
group, diastolic (DBP) and systolic (SBP) blood pres-
sures were measured at the beginning of the experiments 
by tail-cuff plethysmography (BP-2000; Visitech Sys-
tems, Apex, North Carolina, USA). Mean blood pressure 
(MBP) was calculated as previously described [25]. DBP, 
SBP, and MBP values were reported in Table 1.
Tissue staining and immunohistochemistry
WKY and SHR (n = 5/group) were anaesthetized and per-
fused with normal saline. Hearts were extracted, washed 
in PBS, fixed with 10% phosphate-buffered formalin and 
paraffin embedded, then 5  µm-thick sections were cut 
from each sample. Masson’s trichrome staining kit was 
used to perform the assay (Bio-Optica, #04-010802). For 
immunohistochemistry assays, formaldehyde-fixed paraf-
fin sections were kept 35 min at 97.5 °C in 9 mM sodium 
citrate pH 6.0. Endogenous peroxidase activity was 
quenched with 3%  H2O2 for 10  min; incubation of pri-
mary antibodies was performed overnight (O/N). Stain-
ing was performed with 3,3-diaminobenzidine (DAB) as 
a chromogen. Slides were immunostained in the same 
batch, including negative controls lacking the primary 
antibody. Antibodies raised against TGF-β1 (AbCam, 
ab64715, clone 9016) and ανβ5 (AbCam, ab179475, clone 
EPR16800) were used. As a negative control, species- and 
isotype-matched IgGs were incubated in place of the pri-
mary antibodies. Serial sections derive from comparable 
areas of the left rat heart ventricle, and were viewed with 
AxioSkop microscope equipped with AxioCam camera 
(Carl Zeiss) and analyzed with AxioVision 4.7 software 
(Carl Zeiss). The positive areas for TGF-β1 and ανβ5 on 
heart samples were normalized to the section area, calcu-
lated with AxioVision 4.7 software (Carl Zeiss).
Cell isolation and culture
WKY and SHR (n = 5) were anaesthetized by 2% isoflu-
rane and euthanized by cervical dislocation. Primary CF 
were isolated from rat whole hearts by the following pro-
tocol. Hearts were extracted with sterile pliers and placed 
in tubes with sterile DMEM High Glucose, with 1% peni-
cillin/streptomycin, 0.5% gentamicin, and 1% ampho-
tericin B (EuroClone). Cardiac tissue was transferred 
Table 1 Diastolic, systolic, and  mean arterial blood 
pressure in WKY and SHR rat groups
Blood pressure values are expressed as mean ± SD, n = 10/group
DBP diastolic blood pressure, SBP systolic blood pressure, MBP mean blood 
pressure
Student’s t-test: ***p < 0.0001
WKY (n = 10) SHR (n = 10)
DBP (mmHg) 92 (± 10) 123 (± 14) ***
SPB (mmHg) 107(± 6) 143 (± 7) ***
MBP (mmHg) 97 (± 9) 97 (± 8) ***
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onto a tissue culture glass dish and minced using dispos-
able sterile scalpels. Tissue fragments were incubated at 
37 °C for 15 min in 10 ml of digestion buffer, composed 
by phosphate buffer saline (PBS, Euroclone), 1% penicil-
lin/streptomycin, 1% Amphotericin B, and Liberase TH 
Research Grade Blendzyme (Roche). After washing 3 
times with PBS, digested tissue fragments were cultured 
on vitronectin-coated dishes at 37 °C, 5%  CO2 in DMEM 
High Glucose (EuroClone) supplemented with 15% Fetal 
Bovine Serum (FBS, EuroClone), 2  mM l-glutamine, 
200  U/ml penicillin, 200  μg/ml streptomycin, and 0.5% 
Amphotericin B. For the signaling experiments, CF were 
serum starved and treated with 5 ng/ml TGF-β1 (Pepro-
tech) for 30  min, while, for the other experiments, cell 
were treated with 5 ng/ml TGF-β1 and 0.5 μM cilengitide 
(MedChem Express) for 48  h. For stiffness-dependent 
experiments, two substrates of known stiffness (4.1 kPa, 
30 kPa) were produced by varying the content of acryla-
mide and the ratio acrylamide/bisacrylamide, accord-
ing to a previously published method [26]. Briefly, small 
drops (70 μl) of polyacrylamide solution were deposited 
onto glass slides (30 mm diameter); glass coverslips, pre-
viously treated with Surfacil (Pierce) were placed on the 
top of the solution drops and kept under nitrogen flow, 
until thin uniform polyacrylamide gels were formed. 
Finally, polyacrylamide gels surface was chemically acti-
vated (Sulfo-SANPAH-Pierce), and coated by vitronectin 
solution (ThermoFisher, #A14700) incubation O/N at 
4 °C. Substrate sterilization was performed by 30 min UV 
(254 nm) light exposure.
ImageStreamX assay
Nuclear translocation of active form of SMAD2 in CF 
after TGF-β1 treatment was evaluated by ImageStreamX 
flow cytometer, a flow cytometric technique combined 
with a fluorescence microscope (ImageStreamX Mark II, 
Amnis). WKY-CF and SHR-CF were serum starved and 
treated for 3  h with 5  ng/ml TGF-β1 (Peprotech). Cells 
were detached from Petri dishes by using a nonenzymatic 
method (TripLE™ Select, Gibco), then, in order to allow 
primary antibody hybridization, CF were fixed, permea-
bilized by using BD Cytofix/Cytoperm kit (BD Pharmin-
gen, 554714, clone EP567Y), and then incubated in the 
dark for 15  min with 0.5  μg/ml anti-SMAD2 primary 
antibody conjugated with FITC (Abcam, ab196320). Each 
sample was then washed with 1 ml of washing buffer and 
centrifuged for 10  min at 400×g to remove unbound 
antibody. Cells were resuspended in 100  μl of FACS 
buffer, composed by PBS supplemented with 0.1% BSA 
(Gibco) and 5 mM EDTA (Gibco), incubated with 2.5 μM 
nuclei fluorescent staining DRAQ5 (Abcam, ab108410), 
and analyzed. Instrument and INSPIRE software were set 
up as follows: channel (Ch) 01 for brightfield, Ch02 for 
FITC fluorescence intensity, Ch05 for APC fluorescence 
intensity, and Ch06 for side-scatter intensity. All samples 
were acquired with a magnification of 40× at a low flow 
rate (high sensitivity), and 488 nm, 630 nm, and 785 nm 
lasers were activated for FITC fluorescence, APC fluo-
rescence, and side-scatter intensity, respectively. CF were 
gated on a dot plot reporting area (“x” axis) and aspect 
ratio (“y” axis) to eliminate cell clumps. A total of 10,000 
events in the CF gated area were acquired. Image analy-
sis was performed using the IDEAS image software. The 
degree of fluorescence relative to SMAD2-FITC staining 
was quantified using the Intensity_MC_Ch02, whereas 
DRAQ5 staining was quantified using the Intensity_MC_
Ch05. To evaluate FITC-APC overlapping signal, indi-
cating the nuclear translocation of SMAD2, a Similarity 
Dilate index analysis on Intensity_MC_Ch02 and Inten-
sity_MC_Ch05 was performed. In this context, the Simi-
larity Dilate index expresses the number of events (cells) 
in which FITC signal (SMAD2) is co-localized with the 
APC signal (DRAQ5).
mRNA extraction and qRT‑PCR
WKY-CF and SHR-CF were cultured and contemporary 
treated with 5 ng/ml recombinant TGF-β1 and/or 0.5 μM 
cilengitide for 48 h. RNA was isolated with a Total RNA 
Purification kit (Norgen Biotek corp.). RNA quantifica-
tion was determined with Spectrophotometer ND-1000 
 (NanoDrop®, EuroClone). Reverse transcription was 
conducted with the SuperScript III (ThermoFisher, 
#18080093) following the manufacturer’s instructions. 
qRT-PCR was performed on the iQ™ SYBR Green Super 
Mix (Bio-Rad, #1725125). 5  ng of cDNA were used to 
quantify the expression of the following genes: acta2 
(FW: TGC CAT GTA TGT GGC TAT TCA; RV: ACC AGT 
TGT ACG TCC AGA AGC), itgav (FW: TCG CAG GGC 
TCA ACA TAT G; RV: CTC TCA ATC TCA CCT CCA 
CAG), and tgfb1 (FW: ATG ACA TGA ACC GAC CCT TC; 
RV: GAT CCA CTT CCA ACC CAG G). All reactions were 
performed in a 96-well format in the iQ5™ (Bio-Rad). 
The relative quantities of specific mRNAs were obtained 
with the use of the comparative Ct method and were nor-
malized to GAPDH gene (FW: TGA AGG TCG GTG TGA 
ACG G; RV: TCA ATG AAG GGG TCG TTG AT).
Western blot analysis
WKY-CF and SHR-CF were contemporary treated with 
5  ng/ml recombinant TGF-β1 and/or 0.5  μM cilen-
gitide for 48  h, and lysed in cell lysis buffer (Cell Sign-
aling Technology, #9803) supplemented with protease 
and phosphatase inhibitor cocktails (Sigma-Aldrich). 
The same lysis buffer solution was used for total protein 
tissue extracts. Total cell and tissue proteins were sub-
jected to SDS-PAGE and transferred onto a nitrocellulose 
Page 4 of 13Perrucci et al. J Transl Med          (2018) 16:352 
membrane. The membranes were blocked for 1  h at 
room temperature in 5% non-fat dry milk in wash buffer 
(Tris Buffer Sulfate 1×, 0.1% Tween 20) and then incu-
bated O/N at 4  °C with the appropriate primary anti-
body. The primary antibodies were specific for TGF-β1 
(AbCam, ab64715, clone 9016), phospho-SMAD2 
(Ser465/467)/SMAD3 (Ser423/425) (Cell Signaling, 
#8828, clone D27F4), SMAD2/3 (Cell Signaling, #3102), 
α-SMA (Merck Millipore, CBL171, clone ASM-1), ανβ3 
(AbCam, ab7166, clone BV3), ανβ5 (AbCam, ab179475, 
clone EPR16800), and collagen I (AbCam, ab34710). The 
membranes were incubated at room temperature with 
peroxidase-conjugated secondary antibodies for 1 h. Sig-
nals were visualized using enhanced chemiluminescence 
Western blotting detection system (GE Healthcare). Pro-
teins were normalized according to β-tubulin (Sigma-
Aldrich, T9026, clone DM1A). Images were acquired 
with Alliance Mini 2M (UVITec Cambridge) and the den-
sitometric analysis of membranes was performed using 
the Alliance Mini 4 16.07 software (UVITec Cambridge).
TGF‑β1 levels in conditioned medium of CF
WKY-CF and SHR-CF were treated with 0.5  μM cilen-
gitide for 48  h, then supernatant conditioned media 
were collected and stored. TGF-β1 levels in condi-
tioned medium were detected with an ELISA kit (LSBio, 
LS-F12740) following the manufacturer’s instructions.
Immunofluorescence
WKY-CF and SHR-CF were plated on Chamber Slides 
(Nunc) and placed in growth for 24 h with 95% humid-
ity and 5%  CO2. CF were treated as previously described 
for 48 h. Then, slides were rinsed with PBS solution and 
soaked for about 15  min in a solution of 4% Paraform-
aldehyde (PFA). The primary unconjugated antibody 
raised against α-SMA (Merck Millipore, CBL171, clone 
ASM-1) was incubated O/N at 4 °C. The goat anti-mouse 
IgG1 secondary antibody conjugated with AlexaFluor488 
(ThermoFisher, #A-21121) was incubated for 1 h at room 
temperature. As a negative control, species- and isotype-
matched IgGs were incubated in place of the primary 
antibodies. Slides were viewed with Apotome micro-
scope equipped with AxioCam camera (Carl Zeiss) and 
analyzed with AxioVision 4.7 software (Carl Zeiss).
Statistical analyses
Quantitative results are expressed as mean ± SD. Statis-
tical significance was evaluated with GraphPad Prism 5. 
Variables were analyzed by Student’s t-test and 2-way 
ANOVA, followed by a post hoc analysis using the Bon-
ferroni post-test. A value of p ≤ 0.05 was deemed statisti-
cally significant.
Results
Hypertensive rat hearts show higher fibrosis and TGF‑β1 
expression than normotensive controls
It is well known that a common feature of hypertension is 
LVH, mainly characterized by the cardiac tissue remod-
elling, in which TGF-β1 plays a major role as molecular 
mediator of ECM alterations [2, 27]. For all these reasons, 
a Masson’s trichrome staining and an immunohisto-
chemistry assay for TGF-β1 were performed in order to 
detect both collagen deposition and TGF-β1 expression 
on heart sections of SHR (n = 5) and WKY (n = 5) rats. 
Consistently, as highlighted in Fig.  1, cardiac tissues of 
hypertensive rats (SHR) showed a higher collagen depo-
sition in perivascular region (Fig.  1a, b), together with 
an augmented TGF-β1 expression in comparison with 
normotensive (WKY)  controls (Fig.  1a, c). To further 
confirm this immunohistological result, a Western bot 
analysis was performed to evaluate in-depth the TGF-β1 
expression level in total protein extracts from WKY and 
SHR heart tissue (Fig. 1d). Figure 1d confirmed the result 
previously showed in Fig. 1a, c.
Thus, hypertensive stimulus leads to a higher collagen 
and TGF-β1 expression on cardiac tissue.
SMAD2/3 signaling activation and α‑SMA expression levels 
are higher in SHR‑CF after TGF‑β1 treatment
To date, the detrimental role played by TGF-β1 on CF in 
the adverse hypertension-derived myocardial remodel-
ling is well established [28]. Thus, to better investigate the 
molecular pathways specifically activated in these cells, CF 
were isolated from the heart of each rat strain (n = 5 WKY, 
n = 5 SHR) for in vitro treatments and subsequent evalua-
tions. Firstly, a full characterization of CF was performed, to 
evaluate the fibroblastic nature of these cells. Immunofluo-
rescence and FACS analyses revealed that isolated CF were 
mesenchymal vimentin-positive cells (Additional file  1: 
Figure S1A), negative for cardiomyocyte, endothelial, and 
inflammatory cell markers (Additional file  1: Figure S1B). 
Then, in order to in-depth investigate the activation of TGF-
β1 pathway in terms of SMAD2/3 signaling, ImageStreamX 
and Western blot analyses were performed. Figure  2a, b 
revealed a significantly higher nuclear translocation of 
SMAD2/3, subsequent to its phosphorylation (shown in 
Fig. 2c), in SHR-CF when compared to WKY-CF. Moreover, 
this event was further emphasized in the same cells after 
5  ng/ml TGF-β1 treatment. In addition, several studies in 
the last years well defined α-SMA as a downstream product 
of TGF-β1/SMAD signaling, as well as an essential media-
tor involved in the CF differentiation into MyoFB [29]. Fig-
ure  2d clearly showed, by Western blot analysis, a strong 
up-regulated α-SMA expression of SHR-CF in compari-
son with WKY-CF. In depth, SHR-CF showed a statistical 
increase of α-SMA protein expression at baseline after 48 h 
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of culture when compared to untreated WKY-CF. Moreo-
ver, in both CF types 48  h of TGF-β1 treatment exacer-
bates the up-regulation of α-SMA, which resulted strongly 
increased specifically in SHR-CF. Similarly, the expression 
of acta2 gene, encoding α-SMA protein, was statistically 
higher in SHR-CF after TGF-β1 treatment than in untreated 
CF of both rat strains and also in comparison with TGF-β1 
treated WKY-CF (Fig. 2e).
All these data suggest that cultured SHR-CF (i) display a 
constitutively activated SMAD2/3 signaling together with a 
greater responsiveness to TGF-β1 and (ii) are more prone 
to differentiate into MyoFB by expressing a higher amount 
of α-SMA when compared to WKY-CF.
ανβ5 gene and protein expression is up‑regulated 
both in SHR cardiac tissue and SHR‑CF
Several previous data suggested a massive involvement 
of different component of integrin protein family in 
TGF-β1 activation by mechanotransduction mecha-
nism, but little is still known about the effect of hyper-
tension and TGF-β1 signaling in integrin expression on 
CF. Thus, we evaluated the expression of integrin ανβ3 
and ανβ5 by Western blot on WKY and SHR rat heart 
tissue protein extract, to understand on which integrin 
deepen the in  vitro investigations. The results of this 
assay, shown in Fig.  3a, clearly highlighted the higher 
expression of integrin ανβ5 in tissue samples than 
Fig. 1 Collagen deposition and TGF-β1 expression are higher in SHR than WKY rat cardiac tissue. a Representative images of Masson’s trichrome 
staining, TGF-β1 immunostaining and relative secondary antibody negative control, on normotensive (WKY) and hypertensive (SHR) rat heart 
tissue samples. Quantification of collagen fibres (b blue signal in Masson’s trichrome staining) and TGF-β1 posive areas (c brown signal in 
immunohistochemistry) in WKY (white bars) and SHR (red bars) left ventricle samples. All histological quantifications are expressed as mean ± SD, 
n = 5/group. Scale bars = 100 μm. d TGF-β1 expression levels in WKY and SHR heart tissue protein extracts. Western blot quantification data are 
expressed as mean ± SD after β-tubulin normalization, n = 5/group. Student’s t-test: *p < 0.05; ***p < 0.0001
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integrin ανβ3. In depth, the integrin ανβ5 expression 
resulted statistically higher in SHR than WKY cardiac 
tissue. The results collected by immunohistochemis-
try on tissue confirmed the higher expression of ανβ5 
in SHR vs. WKY cardiac tissue (Fig.  3b, c). In order 
to evaluate the integrin ανβ5 expression levels also 
in vitro, SHR- and WKY-CF were treated with TGF-β1, 
then both Western blot and qRT-PCR assays were per-
formed on protein and total RNA extracts, respectively. 
Integrin ανβ5 protein expression was statistically 
higher in SHR-CF after 48  h of TGF-β1 treatment in 
comparison with untreated SHR-CF and WKY-CF with 
and without TGF-β1 treatment (Fig. 3d). Real-time data 
demonstrated a statistically higher up-regulation of 
integrin αν subunit gene expression in untreated SHR-
CF vs. WKY-CF; the statistical difference was, also in 
this case, enhanced by TGF-β1 treatment (Fig. 3e).
These findings suggest that hypertension is a sufficient 
stimulus in promoting integrin ανβ5 over-expression 
Fig. 2 TGF-β1 treatment increases SMAD2/3 signaling activation and α-SMA expression levels more in SHR-CF than in WKY-CF. a Results obtained 
by ImageStreamX (IMX) technology, on SMAD2 nuclear translocation in WKY- and SHR-CF before and after 3 h of TGF-β1 treatment. IMX microscopy 
images were obtained on fixed and permeabilized CF, hybridized with anti-SMAD2-FITC antibody (green), and stained with DRAQ5 for the nucleus 
(red). Merged signal (yellow) indicates SMAD2 signal after nuclear translocation. b IMX fluorescence-activated cell sorting analysis on data collected 
from 10,000 events/sample. Bar graph indicates the similarity dilate index of WKY-CF (white bars) and SHR-CF (red bar), without and with TGF-β1 
treatment. Scale bar = 10 μm. c Phospho-SMAD2/3 and total SMAD2/3 expression levels in WKY- and SHR-CF after 30 min of treatment with 5 ng/
ml of recombinant TGF-β1. α-SMA protein (d) and gene (e) expression in WKY- and SHR-CF after treatment with 5 ng/ml TGF-β1. Western blot 
quantification data are expressed as mean ± SD after β-tubulin normalization, qRT-PCR data are expressed as fold ± SD normalized with GAPDH 
gene, n = 5/group. The experiments on cells were performed in triplicate. 2-way ANOVA with Bonferroni’s post-test: *p < 0.05, ***p < 0.001
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on cardiac tissue and also that the TGF-β1 is an effec-
tive mediator in stimulating up-regulation of ανβ5 
transcription and production in SHR-CF.
Specific ανβ5 blockade in vitro decreases typical MyoFB 
protein expression in SHR‑CF
To evaluate whether integrin ανβ5 may be considered a 
putative pharmacological target in the adverse alteration 
of hypertensive-derived fibrosis, cilengitide was used as 
αν RGD integrin inhibitor for in  vitro evaluations. To 
assess the cytotoxicity of this integrin inhibitor com-
pound, a dose–response assay by MTT internalization 
(Additional file  1: Figure S2) was performed. Simulta-
neously, to evaluate the more effective concentration of 
cilengitide in  vitro on CF, an ELISA assay (Fig.  4a) was 
further performed. Taken together, these results con-
firmed that cilengitide is not significantly toxic at the 
concentration of 0.5 μM. Furthermore, the integrin ανβ5 
inhibitor at the same concentration is able in strongly 
decreasing the TGF-β1 release by SHR-CF  in the con-
ditioned medium. After that, as depicted in Fig.  4b, the 
protein expression of integrin ανβ5 was consistently and 
significantly down-regulated after 48  h of 0.5  μM cilen-
gitide treatment when compared with TGF-β1 treatment 
in SHR-CF. It is noteworthy that integrin ανβ5 levels are 
statistically higher in SHR-CF vs. WKY-CF, but cilen-
gitide treatment specifically rescued this protein expres-
sion in SHR-CF to the levels of untreated condition. In 
fact, it is also important to point out how cilengitide is 
more effective on SHR-CF than in WKY-CF in counter-
acting the TGF-β1 activity.
As previously reported, the main features of activated 
MyoFB are (i) the higher expression of α-SMA, which 
gives a contractile phenotype to these cells, and (ii) the 
Fig. 3 Integrin ανβ5 expression is higher both in SHR cardiac tissue and in SHR-CF than respective controls. a Integrin ανβ5 and ανβ3 expression 
levels in WKY (white bars) and SHR (red bars) heart tissue protein extracts. Western blot quantification data are expressed as mean ± SD after 
β-tubulin normalization, n = 5/group. Student’s t-test: *p < 0.05. b, c Integrin ανβ5 immunohistochemistry and relative secondary antibody negative 
control on normotensive (WKY) and hypertensive (SHR) rat heart sample (b). Integrin ανβ5 positive areas were quantified and normalized on 
whole sample area (c). Student’s t-test: *p < 0.05. Scale bar = 100 μm. Integrin ανβ5 protein (d) and itgav gene (e) expression in WKY- and SHR-CF 
after treatment with 5 ng/ml TGF-β1. Western blot quantification data are expressed as mean ± SD after β-tubulin normalization, qRT-PCR data are 
expressed as fold ± SD normalized with GAPDH, n = 5/group. The experiments on cells were performed in triplicate. 2-way ANOVA with Bonferroni’s 
post-test: *p < 0.05
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greater production of collagen I and other ECM proteins, 
which strongly contribute to cardiac reactive fibrosis. 
Both these features were evaluated in our in vitro model: 
Western blot and immunofluorescence analyses were 
performed after 48  h of treatments. Specifically, integ-
rin inhibition deeply diminished collagen I production in 
CF of both rat strains (Fig.  4c). Although the collagen I 
protein levels in SHR-CF were overall higher than those 
expressed by WKY-CF, in both CF cell types cilengitide 
treatment significantly down-regulated collagen I expres-
sion. Markedly, the collagen I level expressed by SHR-CF 
after cilengitide treatment was significantly lower than 
untreated SHR-CF, even reaching the expression levels 
of untreated WKY-CF. Similar results were obtained by 
immunofluorescence assays and Western blot analysis 
on α-SMA expression (Fig.  4d, e), where it was clearly 
showed an overall strong up-regulation of α-SMA in 
SHR-CF when compared with WKY-CF. In the context 
of immunofluorescence assay, it is important to point 
out that the inhibition of integrin mediated by cilengitide 
together with the repetitive cell washes, necessary in this 
technique, led to a lower number of attached cells on the 
chamber slides. For this reason and also in order to have 
a more quantifiable data, the Western blot assay was per-
formed to provide the evidence on cilengitide effects on 
α-SMA.
As for collagen I, another pro-fibrotic mediator expres-
sion, such as laminin (Additional file  1: Figure S3A), 
resulted modulated by cilengitide, even in presence of 
TGF-β1. Real-time results on modulation of tgfb1 gene, 
encoding TGF-β1, on CF after treatments were consist-
ent with previously observed data on ανβ5, collagen I, 
and laminin protein assays. In fact, tgfb1 was signifi-
cantly down-regulated after 24  h of 0.5  μM cilengitide 
Fig. 4 Integrin ανβ5 blockade in vitro decreases TGF-β1 release and protein production of typical MyoFB markers. a Secreted amount of active 
TGF-β1 in conditioned media of WKY- and SHR-CF after treatments with 0.5 μM cilengitide. ELISA data are expressed as mean ± SD, n = 5/group. 
The experiments on cell surnatants were performed in triplicate. Protein expression of integrin ανβ5 (b) and collagen I (c) in WKY- and SHR-CF after 
treatments with 5 ng/ml TGF-β1, TGF-β1 + 0.5 μM cilengitide, or cilengitide. d Representative images of immunofluorescence performed for α-SMA 
on WKY- and SHR-CF. Scale bar = 100 μm. e Protein expression of α-SMA in WKY- and SHR-CF after treatments with 5 ng/ml TGF-β1, TGF-β1 + 0.5 μM 
cilengitide, or cilengitide. All Western blot quantification data are expressed as mean ± SD after β-tubulin normalization. The experiments on cells 
were performed in triplicate, with a n = 5/group. 2-way ANOVA with Bonferroni’s post-test: *p < 0.05, **p < 0.01, ***p < 0.001
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treatment when compared with TGF-β1 treatment, in 
both CF cell lines (Additional file  1: Figure S3B). It is 
important to highlight how tgfb1 levels were statistically 
higher in SHR-CF vs. WKY-CF, but cilengitide treatment 
rescued this gene expression to that of untreated cells. 
Noteworthily, as for ανβ5, collagen I, and laminin levels, 
cilengitide is more effective on SHR-CF than in WKY-CF 
in fixing the detrimental effects of TGF-β1.
So, these data suggest that cilengitide activity strongly 
reduces the fibrotic progression in terms of MyoFB dif-
ferentiation of CF, especially in SHR-CF.
A higher stiffness of cell growth substrate exacerbates 
integrin ανβ5 and collagen I expression, as well 
as cilengitide effectiveness, in SHR‑CF
By a cellular point of view, the most detrimental event 
in cardiac fibrosis is the persistent activation of MyoFB, 
which causes an excessive deposition of collagen, cul-
minating in the scar formation. This disproportionated 
increase of ECM, which is markedly stiff, plays a nega-
tive role leading to a cronically impaired heart function. 
Therefore, to better describe the integrin involvement in 
CF on the basis of different rigidity of growth substrates, 
Western blot analyses for integrin ανβ5 (Fig.  5a, b) and 
collagen I (Fig.  5a, c) were performed on total protein 
extracts of CF seeded on two different substrates and 
then treated with TGF-β1 and/or cilengitide. The sub-
strates were defined at high stiffness (41 kPa), similar to 
that of plastic, and low stiffness (30 kPa). The results col-
lected with CF growing on high stiffness were strongly 
similar to the previous results obtained on plastic sup-
port, showing a strong up-regulation of integrin ανβ5 and 
collagen I protein levels in SHR-CF vs. WKY-CF. Also in 
this experimental setting, TGF-β1 enhanced the protein 
expression of both markers as well as cilengitide was 
effective in counteract the TGF-β1 detrimental effect in 
both cell lines and able to downregulate the ανβ5 expres-
sion more efficiently in SHR-CF than in WKY-CF. On the 
contrary, the entire system was de-regulated in presence 
of a lower stiff cell growth substrate. In depth, both CF 
lines expressed lower amount of integrin and collagen I 
in comparison with the same cells, growing on a harder 
stiffness. However, cilengitide was able to downregulate 
integrin expression in both CF lines also on a lower stiff-
ness. Importantly, despite the lower stiffness of substrate, 
SHR-CF resulted more responsive to TGF-β1 effect in 
terms of collagen I, but not of integrin ανβ5, synthesis. 
Remarkably, cilengitide treatment resulted effective in 
downregulate also collagen I protein levels.
Discussion
In this study we found a direct effect of hypertension on 
integrin-mediated TGF-β1 activation and, by in  vitro 
experiments, the positive effects of cilengitide treatment 
in decreasing the fibrosis progression by integrin ανβ5 
inhibition.
In the last years numerous investigators reported a cru-
cial role played by the integrin-mediated TGF-β1 signal-
ing in ECM remodelling occurring in cardiac fibrosis [30] 
and the subsequent LVH [31], which are, in turn, strongly 
associated with hypertension and angiotensin II signaling 
[32–34].
The first findings of our study revealed a typical 
perivascular fibrosis in cardiac tissues of hypertensive rat, 
defining a pro-fibrotic scenario in this animal model. This 
perivascular fibrosis, strongly consistent with previous 
investigations [35], was indeed associated with a general 
hypertension-derived cardiac hypertrophy, underlined by 
the augmented area of cardiac fibre nuclei [36, 37]. Fur-
thermore, our results were additionally corroborated by 
a strong up-regulation in cardiac tissue of TGF-β1, key 
mediator of fibrosis.
All these results on cardiac tissue matched with in vitro 
evidence: SHR-CF expressed higher levels of α-SMA gene 
and protein vs. WKY-CF. This led to define these cells 
as contractile and active MyoFB. Consistently, to date is 
well-known the detrimental contribution of MyoFB in 
collagen deposition and ECM remodelling during fibrotic 
process, leading to irreversible organ dysfunction [28, 
38, 39]. Moreover, MyoFB contraction has been shown 
to directly activate latent TGF-β1, stored in the ECM, by 
integrin-mediated binding [13, 40]. In fact, it has been 
extensively reported that fibroblasts, in which α-SMA 
expression is quite low, are less efficient in the TGF-β1 
activation when compared with α-SMA+ MyoFB [3, 40]. 
In light of all these findings, it can be speculated that the 
hypertensive stimulus, fostered by TGF-β1 treatment, is 
able to push CF into a pro-fibrotic state, characterized by 
the up-regulation of TGF-β1/SMAD signaling leading to 
CF differentiation into MyoFB.
An interesting evidence outlined here is the over-acti-
vation of TGF-β1/SMAD signaling in SHR-CF, which 
is usually maintained in these cells over several cell 
divisions (data not shown). These findings suggested 
a chronic activation of the canonical TGF-β1 signal-
ing pathway in CF of hypertensive rats, suggested by 
the reactivity of starved cells, and further resulting by 
an increased TGF-β reservoir in SHR heart, determin-
ing an autocrine loop. It is really important to point 
out that, although cultured SHR-CF showed intrinsi-
cally enhanced TGF-β1 signaling activation, these cells 
still strongly responded to exogenous TGF-β1, espe-
cially when growing on a substrate with higher stiffness. 
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This evidence indicated that the in  vivo hypertensive 
heart context, more rigid and burdened of latent TGF-
β1, rendered SHR-CF more prone and reactive to pro-
fibrotic molecular mediators. Among these pro-fibrotic 
mediators, we can include now also the integrin ανβ5, 
which displayed in our experimental results higher lev-
els in the SHR heart tissue and in cultured SHR-CF. In 
2014, Sarrazy et al. [18] showed, by an in vitro model of 
human ventricular CF, that the mechanical stimulus (e.g. 
contraction) activated integrin ανβ5-mediated release 
of latent TGF-β1. Altogether, these data suggested how 
hypertension-derived mechanical stress modulated the 
integrin ανβ5 expression, thereby up-regulating and acti-
vating TGF-β1 through its release from the latent com-
plex stored in ECM. Remarkably, our results further draw 
the attention to the role of TGF-β1, which is boosting the 
over-expression levels also of integrin ανβ5, especially in 
SHR-CF.
Fig. 5 In vitro inhibition of integrin ανβ5 by cilengitide limits ανβ5 and collagen I expression more effectively on SHR-CF growing on a substrate 
with high stiffness. a Representative Western blot images of ανβ5 and collagen I protein expression in WKY- and SHR-CF cultured on substrates with 
two different stiffness (high and low) and contemporary treated with 5 ng/ml TGF-β1, TGF-β1 + 0.5 μM cilengitide, or cilengitide. All Western blot 
quantification data (b and c) are expressed as mean ± SD after β-tubulin normalization. The experiments on cells were performed in triplicate, with 
a n = 5/group. 2-way ANOVA with Bonferroni’s post-test: *p < 0.05, **p < 0.01, ***p < 0.001
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All these observation drove us to hypothesize the 
integrin ανβ5 as a putative target for potential pharma-
cological treatment. Recently, Hatley et al. have exten-
sively analyzed all the available tools, which potentially 
may play a therapeutic role by acting as αν integrin 
inhibitors [19]. Among these numerous compounds, 
we selected cilengitide, because of its deep involve-
ment in pre-clinical and clinical studies [19]. Cilen-
gitide was tested in experimental fibrotic diseases, such 
as trinitrobenzene sulfonic acid-induced colitis, and its 
efficacy in inhibiting the fibrosis through the blocking 
of integrin-mediated activation of latent TGF-β was 
confirmed both in human and rat intestinal smooth 
muscles [41]. Moreover, a recent study evaluated the 
effectiveness of cilengitide in regression of fibrosis on 
a murine model of systemic sclerosis, a largely known 
fibrotic systemic disease [42].
In this study, for the first time, we obtained astonish-
ingly evidence on effective inhibition of integrin ανβ5 by 
cilengitide in our hypertensive-derived in  vitro model. 
The experiments performed allowed us to evaluate dif-
ferent aspects of integrin inhibition. Firstly, the integrin 
inhibition mediated by cilengitide is necessary and suf-
ficient to decrease the levels of released TGF-β1, which 
form is able to activate its negative effects. Despite cilen-
gitide does not directly inhibit TGF-β1 but its release, 
we surprisingly observed that the integrin inhibition 
provoked a decrease in TGF-β1 pro-fibrotic effects in 
terms of integrin ανβ5 expression, as well as of collagen 
I and α-SMA even in presence of TGF-β1. It is impor-
tant to underline that the effects of cilengitide on WKY-
CF are appreciable only as α-SMA protein expression 
levels. This observation is probably due to the superior 
efficacy of cilengitide only in presence of higher integ-
rin ανβ5 expression levels. For this reason, cilengitide 
resulted more effective in SHR-CF than in WKY-CF. The 
results obtained from the analysis of cells on different 
stiffness substrates further strengthened our hypothesis, 
highlighting that this integrin-mediated mechanism is 
strongly stimulated by a substrate with higher rigidity, 
as already reported by literature [43–45]. Subsequently, 
cilengitide action resulted more effective in these condi-
tions. So, in our experiments, treatment with cilengitide 
positively influenced SHR-CF differentiation into MyoFB, 
especially on cells growing in ECM with high stiffness 
and in presence of TGF-β1, decreasing production of 
pro-fibrotic mediators and α-SMA to levels comparable 
to untreated WKY-CF.
Conclusions
Taking into account the numerous important data on 
pro-fibrotic disease prevention by inhibition of αν integ-
rin family [13, 14, 18], this study may help to define a new 
role for integrin ανβ5 in CF differentiation into MyoFB, 
determining this molecule as a novel, considerable, and 
effective target for the treatment of hypertension-derived 
cardiac fibrosis. This study sets the stage for essential 
future in  vivo testing of cilengitide in counteracting the 
detrimental effect of the hypertensive stimulus in cardiac 
fibrosis development.
Additional file
Additional file 1: Figure S1. Isolated WKY- and SHR-CF equally display 
vimentin and express mesenchymal markers, confirming their fibroblast 
nature. (A) Representative images of immunofluorescence for vimentin (in 
green) on fixed WKY- and SHR-CF (nuclei in blue). Scale bar = 100 μm. (B) 
Immunophenotype results and analysis on WKY- and SHR-CF for typical 
mesenchymal (CD90, CD29, CD105), cardiomyocyte (cardiac troponin 
T, cTnT), endothelial (CD31, CD34), and inflammatory cell (CD45, CD14) 
markers. FACS results are expressed as mean cell percentage ± SD, n = 5/
group. Student’s t-test: *p<0.05. Figure S2. Dose-response assay on CF 
treated with different cilengitide concentration. (A) Cell vitality by MTT 
assay after treatments with three different concentration of cilengitide 
(0.5, 5, 50 μM). MTT assay quantification data are expressed as mean 
percentage ± SD. The experiments on cells were performed in triplicate, 
with a n = 3/group. Student’s t-test: *p<0.05, **p<0.01. (B) Representa-
tive image of MTT assay on 12-multiwell plate. Figure S3. Cilengitide 
inhibition of integrin ανβ5 downregulates laminin protein expression by 
modulating TGF-β1 gene trascription. (A) Protein expression of laminin in 
WKY- and SHR-CF after treatments with 5 ng/ml TGF-β1, TGF-β1 + 0.5 μM 
cilengitide, or cilengitide. Western blot quantification data are expressed 
as mean ± SD after β-tubulin normalization. (B) Gene expression of 
TGF-β1 on WKY- and SHR-CF after treatments with 5 ng/ml TGF-β1, 
TGF-β1 + 0.5μM cilengitide, or cilengitide. qRT-PCR data are expressed as 
fold ± SD normalized with GAPDH. All the experiments on cells were per-
formed in triplicate, with a n = 5/group. 2-way ANOVA with Bonferroni’s 
post-test: *p<0.05, **p<0.01, ***p<0.001.
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